Novartis AG risk profile
33 Normal where most of the sector sits
Measured 20 September 2026 from NOVN's filed statements. Recomputed nightly.
33 (Normal), driven by Competitive position at 40, over 3 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 24 | Normal | Stable | One-year price volatility — 23.7% |
| Operating pressure | 22 | Normal | Worsening | Costs outgrowing revenue — -3.2 percentage points |
| Cash conversion | Reads operating_cashflow, capital_expenditure, free_cashflow, net_income and revenue. No reading is stored for this company. | |||
| Leverage and coverage | Reads total_debt, cash_and_cash_equivalents, ebitda, interest_expense, total_current_assets, total_current_liabilities and a disclosed CET1 ratio, for a bank or insurer. No reading is stored for this company. | |||
| Competitive position | 40 | Elevated | Stable | Operating-margin gap against peers — +5.0 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.